Cellectar Biosciences, Inc. Deferred Offering Costs
Cellectar Biosciences, Inc. (CLRB) had Deferred Offering Costs of $159.30 thousand as of 2011-09-30, per its 10-Q filed 2011-11-07.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2011-11-07
- 2011-09-30: Deferred Offering Costs $159.30K.
- 2011-06-30: Deferred Offering Costs $57.70K.
| Period end | Deferred Offering Costs |
|---|---|
| 2011-09-30 | $159.30K 10-Q · filed 2011-11-07 |
| 2011-06-30 | $57.70K 10-Q · filed 2011-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |